

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Norucholic acid for treating primary sclerosing cholangitis ID6583**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Dr Falk Pharma (norucholic acid)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Addenbrookes Liver Transplant Association</li> <li>• Black Health Agency For Equality</li> <li>• Bladder and Bowel Community</li> <li>• Bowel Cancer UK</li> <li>• British Liver Trust</li> <li>• Colostomy UK</li> <li>• Crohn's and Colitis UK</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• GUTS UK</li> <li>• IA: Ileostomy and Internal Pouch Group</li> <li>• IBDrelief</li> <li>• Liver4Life</li> <li>• LIVERNORTH</li> <li>• Metabolic Support UK</li> <li>• PSC Support</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Coloproctology for Great Britain and Ireland</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for the Study of the Liver</li> <li>• British Geriatrics Society</li> <li>• British Liver Nurses Forum</li> <li>• British Society of Gastroenterology</li> <li>• British Transplantation Society</li> <li>• NHS Blood and Transplant</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Scottish Society of Gastroenterology</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Dr Falk Pharma (ursodeoxycholic acid)</li> <li>• Glenmark Pharmaceuticals (ursodeoxycholic acid)</li> <li>• Grindecks Kalecks (ursodeoxycholic acid)</li> <li>• Strides Pharma (ursodeoxycholic acid)</li> <li>• Wockhardt (ursodeoxycholic acid)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Hepato-Biliary Group</li> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• Foundation for Liver Research</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> </ul>

Provisional stakeholder list for the evaluation of norucholic acid for treating primary sclerosing cholangitis ID6583

Issue date: March 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Provisional stakeholder list for the evaluation of norucholic acid for treating primary sclerosing cholangitis ID6583  
Issue date: March 2026

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.